We are live on ! Find out more
BCYC

Bicycle Therapeutics
BCYC

81 hedge funds and large institutions have $381M invested in Bicycle Therapeutics in 2022 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 32 increasing their positions, 16 reducing their positions, and 40 closing their positions.

New
Increased
Maintained
Reduced
Closed

852% more call options, than puts

Call options by funds: $1.77M | Put options by funds: $186K

100% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 16

8.4% more ownership

Funds ownership: 68.15% → 76.55% (+8.4%)

23% less funds holding

Funds holding: 105 → 81 (-24)

33% less funds holding in top 10

Funds holding in top 10: 6 → 4 (-2)

57% less capital invested

Capital invested by funds: $884M → $381M (-$503M)

60% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 40

Holders
81
Holders Change
-24
Holders Change %
-22.86%
% of All Funds
1.36%
Holding in Top 10
4
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-33.33%
% of All Funds
0.07%
New
16
Increased
32
Reduced
16
Closed
40
Calls
$1.77M
Puts
$186K
Net Calls
+$1.58M
Net Calls Change
-$20.3M

Top Buyers

Rank Fund Capital Flow
1
PBA
Paradigm Biocapital Advisors
New York
+$22.1M
2
DTC
Deep Track Capital
Connecticut
+$22M
3
CS
Candriam SCA
Luxembourg
+$17.6M
4
LGM
Logos Global Management
California
+$15.8M
5
Morgan Stanley
Morgan Stanley
New York
+$15.5M

Top Sellers

Rank Fund Capital Flow
1
Loomis, Sayles & Company
Loomis, Sayles & Company
Massachusetts
-$28.2M
2
FLSM
Frazier Life Sciences Management
California
-$26.5M
3
GPP
Great Point Partners
Connecticut
-$24.2M
4
EC
EcoR1 Capital
California
-$24M
5
IC
Ikarian Capital
Texas
-$21M
Name Holding Trade Value Shares
Change 		Change in
Stake
Goldman Sachs
26
Goldman Sachs
New York
$2.59M -$189K -8,939 -5%
Renaissance Technologies
27
Renaissance Technologies
New York
$2.57M +$1.87M +88,801 +138%
HS
28
HighVista Strategies
Massachusetts
$2.54M +$2.8M +132,909 +726%
AllianceBernstein
29
AllianceBernstein
Tennessee
$2.22M +$2.79M +132,306 New
DCM
30
DAFNA Capital Management
California
$2.2M +$1.64M +78,000 +147%
Handelsbanken Fonder
31
Handelsbanken Fonder
Sweden
$2.18M – – –
Qube Research & Technologies (QRT)
32
Qube Research & Technologies (QRT)
United Kingdom
$2.09M +$2.44M +115,890 +1,316%
Voloridge Investment Management
33
Voloridge Investment Management
Florida
$2.06M +$2.59M +123,050 New
Allianz Asset Management
34
Allianz Asset Management
Germany
$1.42M +$1.78M +84,485 New
BG
35
Bellevue Group
Switzerland
$1.42M +$1.01M +47,900 +131%
JP Morgan Chase
36
JP Morgan Chase
New York
$1.4M +$1.55M +73,555 +743%
Marshall Wace
37
Marshall Wace
United Kingdom
$1.34M +$1.47M +69,504 +655%
PHP
38
Parkman Healthcare Partners
Connecticut
$1.01M +$66K +3,131 +5%
UOC
39
UBS O'Connor
Illinois
$967K +$1.22M +57,625 New
Acadian Asset Management
40
Acadian Asset Management
Massachusetts
$954K +$442K +20,950 +58%
HCA
41
Harbor Capital Advisors
Illinois
$856K +$466K +22,085 +76%
Victory Capital Management
42
Victory Capital Management
Texas
$561K -$10.9M -518,003 -94%
SG Americas Securities
43
SG Americas Securities
New York
$509K -$1.07K -51 -0.2%
Manulife (Manufacturers Life Insurance)
44
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$431K +$118K +5,603 +29%
EHI
45
Eagle Health Investments
Connecticut
$394K +$496K +23,500 New
AP
46
AtonRa Partners
Switzerland
$386K +$135K +6,394 +38%
SSA
47
Schonfeld Strategic Advisors
New York
$358K +$280K +13,300 +166%
TCM
48
Tekla Capital Management
Massachusetts
$337K +$210K +9,979 +99%
Ensign Peak Advisors
49
Ensign Peak Advisors
Utah
$306K – – –
AA
50
ALPS Advisors
Colorado
$295K +$371K +17,590 New
1
2
3 4 5

BCYC Hedge Fund Activity: Q2 2022 in Review

81 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Bicycle Therapeutics (BCYC) for Q2 2022, worth a combined $381M — down 57% from $884M a quarter earlier.

Sellers outnumbered buyers: 40 funds closed out of BCYC and 16 opened new positions — a net loss of 24 holders — while 16 trimmed existing stakes and 32 added.

The largest buyer was Paradigm Biocapital Advisors, opening a new position worth an estimated $22.1M. The largest seller was Loomis, Sayles & Company, exiting entirely with an estimated $28.2M sold.

  • 81 institutional investors held Bicycle Therapeutics (BCYC) as of Q2 2022, down from 105 in Q1 2022.
  • Funds reported $381M of Bicycle Therapeutics stock for Q2 2022, down 57% quarter-over-quarter.
  • 16 funds opened new Bicycle Therapeutics positions in Q2 2022 and 40 closed out, a net change of -24 holders.
  • The largest Bicycle Therapeutics buyer in Q2 2022 was Paradigm Biocapital Advisors, an estimated $22.1M added.
  • The largest Bicycle Therapeutics seller in Q2 2022 was Loomis, Sayles & Company, an estimated $28.2M sold.

Based on aggregated 13F filings for Q2 2022.